Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Biolexis Therapeutics to Present Late-Breaking Poster at the American Association of Immunologists (AAI) Annual Meeting 2024


AMERICAN FORK, Utah, May 1, 2024 /PRNewswire/ -- Biolexis Therapeutics, Inc. a clinical-stage AI-driven biopharmaceutical company, today announced it will present a late-breaking poster at the 2024 American Association of Immunologists (AAI), taking place May 3-7, 2024, in Chicago, IL.

The conference brings together the top immunology experts for in-depth discussions exploring a wide array of topics, highlighting the latest groundbreaking discoveries in the field. Biolexis' scientific team will be presenting pre-clinical data demonstrating the efficacy of the company's novel PIM1-inhibitor, BLX-0631.

AAI poster presentation details are below:

Title: "Development of highly selective, potent, orally available PIM1 inhibitor BLX-0631 shows a therapeutics potential in Systemic Lupus Erythematosus (SLE) models"
Session Title: Late-Breaking: Therapeutic Approaches to Autoimmunity (PM)
Session Date and Time: Monday May 6, 2024, 2:15 PM - 3:30 PM
Location: Exhibit Hall F1
Poster Board Number: B900
Abstract ID: 6301

More information can be found on the AAI meeting website.

About Biolexis Therapeutics, Inc.
Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, metabolic, neurodegenerative, auto-immune, and inflammatory diseases. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLerntm AI-enabled drug discovery process.

For more information, please visit www.biolexistx.com

SOURCE Biolexis Therapeutics Inc


These press releases may also interest you

at 20:10
/DISREGARD RELEASE: Hidden River Eating Disorder Residential Treatment/
We are advised by Hidden River Eating Disorder Residential Treatment that journalists and other readers should disregard the news release, Hidden River Announces Insurance Contract with Blue Cross Blue Shield, issued 16-May-2024 over PR Newswire....

at 20:00
Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer
Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment of Mark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO). Dr. de Jong, joins Full-Life with 43...

at 19:20
Whitman-Walker Institute Decries Misleading Propaganda About Transgender Health During Congressional Hearing
Whitman-Walker Institute, which leverages research, policy, and education to advance health equity nationwide, says it's standing by to further inform the chair of the U.S. House Committee on Education and the Workforce and others about the strong...

at 18:50
AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc....

at 18:46
FDA APPROVES IMDELLTRAtm (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRAtm (tarlatamab-dlle) for the...

at 18:42
Join Housecall Providers at Toss for a Cause: A Free, Community-wide Event Spotlighting Nonprofit Innovation in Elder and Disability Care
Housecall Providers, a nonprofit home-based medical organization invites the community to Sellwood Park, Saturday, June 1, from noon ? 4:00 p.m. for an inspiring afternoon of learning, connection and some friendly competition. Toss...

More news about Health...


News published on and distributed by: